Toshio Watanabe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Toshio Watanabe has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Masanobu Satake
Department of Molecular Immunology, Institute of Development, Aging and Cancer, Tohoku University, Sendai,1 Hematology and Clinical Immunology, Nishi-Kobe Medical Center, Kobe, Japan,2 Department of Physiology, Jefferson Medical College, Philadelphia, Pennsylvania,3 Hematology Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts4
2 shared publicationsNaomi Yoshida
Department of Molecular Immunology, Institute of Development, Aging and Cancer, Tohoku University, Sendai 980-8575, Japan
2 shared publicationsAtsushi Miyajimaa
1 shared publicationHitoshi Okadad
1 shared publicationKazuyoshi Kohu
Department of Molecular Immunology, Institute of Development, Aging and Cancer, Tohoku University, Sendai,1 Hematology and Clinical Immunology, Nishi-Kobe Medical Center, Kobe, Japan,2 Department of Physiology, Jefferson Medical College, Philadelphia, Pennsylvania,3 Hematology Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts4
1 shared publicationKenji Tanabe
Department of Molecular Immunology, Institute of Development, Aging and Cancer, Tohoku University, Sendai,1 Hematology and Clinical Immunology, Nishi-Kobe Medical Center, Kobe, Japan,2 Department of Physiology, Jefferson Medical College, Philadelphia, Pennsylvania,3 Hematology Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts4
1 shared publication
Latest Publications
- 1 February 2005
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 25 (3) , 1003-1012
Filamin A-Bound PEBP2β/CBFβ Is Retained in the Cytoplasm and Prevented from Functioning as a Partner of the Runx1 Transcription Factor
The heterodimeric transcription factor PEBP2/CBF is composed of a DNA-binding subunit, called Runx1, and a non-DNA-binding subunit, called PEBP2β/CBFβ. The Runx1 protein is detected exclusively in the nuclei of most cells and tissues, whereas PEBP2β is located in the cytoplasm. We addressed the mechanism by which PEBP2β localizes to the cytoplasm and found that it is associated with filamin A, an actin-binding protein. Filamin A retains PEBP2β in the cytoplasm, thereby hindering its engagement as a Runx1 partner. The interaction with filamin A is mediated by a region within PEBP2β that includes amino acid residues 68 to 93. The deletion of this region or the repression of filamin A enables PEBP2β to translocate to the nucleus. Based on these observations, we propose that PEBP2β has two distinct domains, a newly defined regulatory domain that interacts with filamin A and the previously identified Runx1-binding domain.
- 1 February 2005
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 25 (3) , 1003-1012
Filamin A-Bound PEBP2β/CBFβ Is Retained in the Cytoplasm and Prevented from Functioning as a Partner of the Runx1 Transcription Factor
The heterodimeric transcription factor PEBP2/CBF is composed of a DNA-binding subunit, called Runx1, and a non-DNA-binding subunit, called PEBP2β/CBFβ. The Runx1 protein is detected exclusively in the nuclei of most cells and tissues, whereas PEBP2β is located in the cytoplasm. We addressed the mechanism by which PEBP2β localizes to the cytoplasm and found that it is associated with filamin A, an actin-binding protein. Filamin A retains PEBP2β in the cytoplasm, thereby hindering its engagement as a Runx1 partner. The interaction with filamin A is mediated by a region within PEBP2β that includes amino acid residues 68 to 93. The deletion of this region or the repression of filamin A enables PEBP2β to translocate to the nucleus. Based on these observations, we propose that PEBP2β has two distinct domains, a newly defined regulatory domain that interacts with filamin A and the previously identified Runx1-binding domain.
- 1 January 2005
- Published by Begell House Inc. Publishers in Critical Reviews™ in Eukaryotic Gene Expression
- Vol. 15 (3) , 197-206
Biological Implications of Filamin A-Bound PEBP2β/CBFβ Retention in the Cytoplasm
Multiple mechanisms regulate dynamic cytoplasmic-to-nuclear transport of transcription factors. However, little is known about the involvement of cytoskeletal proteins in this process. The heterodimeric transcription factor PEBP2/CBF is composed of a DNA-binding subunit, Runx1, and a non-DNA-binding subunit, PEBP2β/CBFβ. The Runx1 protein possesses nuclear localization signals and is found exclusively in the nucleus, whereas PEBP2β is located in the cytoplasm in most cells and tissues examined thus far. We investigated the mechanism by which PEBP2β localizes to the cytoplasm and found that it associates with filamin A, an actin-binding cytoskeletal protein. Filamin A retains PEBP2β in the cytoplasm, thereby hindering its engagement as a Runx1 partner. When filamin A is absent, PEBP2β moves into the nucleus and enhances Runx1-dependent transcription. These observations highlight the significance of the subcellular localization of PEBP2β in regulating its activity as a component of the PEBP2/CBF transcription factor. In humans, PEBP2β is frequently targeted in the leukemia-associated chromosomal abnormality, inversion 16 (inv 16). Thus, identifying the factors that mediate the subcellular localization of the PEBP2β-derived chimeric transcription factor produced by inv 16 is an important issue that will need to be resolved in order to understand the mechanism(s) involved in inv 16-induced leukemogenesis.
- 1 January 2005
- Published by Begell House Inc. Publishers in Critical Reviews™ in Eukaryotic Gene Expression
- Vol. 15 (3) , 197-206
Biological Implications of Filamin A-Bound PEBP2β/CBFβ Retention in the Cytoplasm
Multiple mechanisms regulate dynamic cytoplasmic-to-nuclear transport of transcription factors. However, little is known about the involvement of cytoskeletal proteins in this process. The heterodimeric transcription factor PEBP2/CBF is composed of a DNA-binding subunit, Runx1, and a non-DNA-binding subunit, PEBP2β/CBFβ. The Runx1 protein possesses nuclear localization signals and is found exclusively in the nucleus, whereas PEBP2β is located in the cytoplasm in most cells and tissues examined thus far. We investigated the mechanism by which PEBP2β localizes to the cytoplasm and found that it associates with filamin A, an actin-binding cytoskeletal protein. Filamin A retains PEBP2β in the cytoplasm, thereby hindering its engagement as a Runx1 partner. When filamin A is absent, PEBP2β moves into the nucleus and enhances Runx1-dependent transcription. These observations highlight the significance of the subcellular localization of PEBP2β in regulating its activity as a component of the PEBP2/CBF transcription factor. In humans, PEBP2β is frequently targeted in the leukemia-associated chromosomal abnormality, inversion 16 (inv 16). Thus, identifying the factors that mediate the subcellular localization of the PEBP2β-derived chimeric transcription factor produced by inv 16 is an important issue that will need to be resolved in order to understand the mechanism(s) involved in inv 16-induced leukemogenesis.
- 1 April 2000
- Published by Elsevier in Developmental Biology
- Vol. 220 (1) , 27-36
The AML1 Transcription Factor Functions to Develop and Maintain Hematogenic Precursor Cells in the Embryonic Aorta–Gonad–Mesonephros Region
- 1 April 2000
- Published by Elsevier in Developmental Biology
- Vol. 220 (1) , 27-36
The AML1 Transcription Factor Functions to Develop and Maintain Hematogenic Precursor Cells in the Embryonic Aorta–Gonad–Mesonephros Region